Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib - Branford, Susan (Journal of clinical oncology. [Englische Ausgabe], 2012)